GLUD1 and liver cancer: In summary, our study provides mechanistic insights into the metabolic adaptation underlying BET inhibition in liver cancer and proposes an option for synthetic lethality targeting GDH1-dependent glutamine metabolism and BET proteins for improved combination treatment of liver cancer.